Tapinarof safe, effective for atopic dermatitis
Tapinarof cream appears to be safe and effective for the treatment of adults and adolescents with atopic dermatitis (AD), a recent study has found.
In this double-blind, vehicle-controlled, randomized, six-arm trial, researchers randomly assigned AD patients to one of six tapinarof dosing regimens: 1 percent twice daily (n=40; median age 27.0 years), 1 percent once daily (n=41; median age 27.0 years), 0.5 percent twice daily (n=43; median age 24.0 years), 0.5 percent once daily (n=41; median age 26.0 years), vehicle twice daily (n=42; median age 23.5 years) and vehicle once daily (n=40; median age 24.0 years).
Treatment success – measured using ad hoc, nonresponder imputation analysis – showed that overall treatment success was more common in the tapinarof-treated groups. At week 12, 53 percent of patients who received 1 percent tapinarof twice daily demonstrated treatment success, as opposed to only 24 percent in those treated twice daily with vehicle.
Notably, during the same time span, twice daily treatment similarly proved superior to once daily treatment (1 percent tapinarof: 53 percent vs 46 percent), though this trend was not apparent at any other time point. Moreover, those treated with 1 percent vs 0.5 percent tapinarof showed better response rates overall.
Treatment-emergent adverse events (TEAEs) were relatively common, reported in 51 percent of the participants. Incidence rate was highest among those treated with 1 percent, twice daily tapinarof (70 percent) and lowest among those who received vehicle once daily (38 percent).
However, most TEAEs were mild-to-moderate in intensity, with nasopharyngitis being the most common. Only 13 patients discontinued the study due to TEAEs.